|
[Related PubMed/MEDLINE] Total Number of Papers: 17
|
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2020 |
A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England. |
CE, DCF, LTTACC, MBG, NMB, PSUB, SDM, TOT, VoI |
2 |
2020 |
An evaluation of managed entry agreements in Belgium: A system with threats and (high) potential if properly applied. |
--- |
3 |
2020 |
Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach. |
--- |
4 |
2020 |
Integrative Review of Managed Entry Agreements: Chances and Limitations. |
--- |
5 |
2020 |
Managed Entry Agreements: Policy Analysis From the European Perspective. |
CED, FBAs |
6 |
2020 |
The impact of managed entry agreements on pharmaceutical prices. |
--- |
7 |
2018 |
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. |
ESMO, HEpc, HTA |
8 |
2018 |
CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA. |
ATC, HTA, MIPs, PBS |
9 |
2018 |
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy. |
SOC |
10 |
2017 |
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. |
CAR, NICE, TPPs |
11 |
2017 |
The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. |
HTA, NICE, P-SUB, PSB, PUB |
12 |
2017 |
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. |
ATC, CEE |
13 |
2017 |
The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia. |
--- |
14 |
2015 |
MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY. |
--- |
15 |
2014 |
Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. |
--- |
16 |
2013 |
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. |
OMPs |
17 |
2011 |
What principles should govern the use of managed entry agreements? |
HTAi |
|